Sign In
Buy PPBT
$1.40
+0.0300 (+2.19%)
At Close: Jul 31, 2026
Purple Biotech Reports First Quarter 2025 Financial Results
07:10am, Wednesday, 21'st May 2025
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
07:30am, Monday, 12'th May 2025
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, i
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
08:28am, Monday, 28'th Apr 2025
REHOVOT, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
08:57am, Monday, 10'th Mar 2025
Completed successful clinical trials for CM24 and NT21 9 oncology assets , demonstrating clinical benefit s and identifying potential biomarkers
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
07:00am, Tuesday, 18'th Feb 2025
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
07:13am, Thursday, 05'th Dec 2024
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
07:13am, Thursday, 05'th Dec 2024
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
12:30pm, Tuesday, 03'rd Dec 2024
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
08:23am, Tuesday, 03'rd Dec 2024
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
Why Is Purple Biotech Stock Trading Higher On Monday?
09:18am, Monday, 02'nd Dec 2024
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with p
Purple Biotech Reports Third Quarter 2024 Financial Results
07:00am, Friday, 15'th Nov 2024
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identif
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
CAPTN-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; A dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cel
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
06:30am, Wednesday, 18'th Sep 2024
REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overc
